Sun Pharma Advanced Research Company Limited (SPARC:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Sun Pharma Advanced Research Company Limited stock forecast from 0 analysts, the average analyst target price for Sun Pharma Advanced Research Company Limited is not available over the next 12 months. Sun Pharma Advanced Research Company Limited’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Sun Pharma Advanced Research Company Limited is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Sun Pharma Advanced Research Company Limited’s stock price was INR 160.71. Sun Pharma Advanced Research Company Limited’s stock price has changed by +14.25% over the past week, +7.19% over the past month and -25.70% over the last year.
No recent analyst target price found for Sun Pharma Advanced Research Company Limited
No recent average analyst rating found for Sun Pharma Advanced Research Company Limited
Company Overview Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India. Read Less
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology....Read More
Frequently Asked Questions About Sun Pharma Advanced Research Company Limited (SPARC:NSE) Stock
Stock Target Advisor's fundamental analysis for Sun Pharma Advanced Research Company Limited's stock is Very Bearish.
Unfortunately we do not have enough data on SPARC:NSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SPARC:NSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SPARC:NSE's stock to indicate if its overvalued.
The last closing price of SPARC:NSE's stock was INR 160.71.
The most recent market capitalization for SPARC:NSE is INR 47.14B.
Unfortunately we do not have enough analyst data on SPARC:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sun Pharma Advanced Research Company Limited's stock.
As per our most recent records Sun Pharma Advanced Research Company Limited has 409 Employees.
Sun Pharma Advanced Research Company Limited's registered address is 17/B, Mahal Industrial Estate, Mumbai, India, 400093.
You can get more information about it from Sun Pharma Advanced Research Company Limited's website at https://www.sparc.life.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Sun Pharma Advanced Research Company Limited (SPARC:NSE) Stock
Stock Target Advisor's fundamental analysis for Sun Pharma Advanced Research Company Limited's stock is Very Bearish.
Unfortunately we do not have enough data on SPARC:NSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SPARC:NSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SPARC:NSE's stock to indicate if its overvalued.
The last closing price of SPARC:NSE's stock was INR 160.71.
The most recent market capitalization for SPARC:NSE is INR 47.14B.
Unfortunately we do not have enough analyst data on SPARC:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Sun Pharma Advanced Research Company Limited's stock.
As per our most recent records Sun Pharma Advanced Research Company Limited has 409 Employees.
Sun Pharma Advanced Research Company Limited's registered address is 17/B, Mahal Industrial Estate, Mumbai, India, 400093.
You can get more information about it from Sun Pharma Advanced Research Company Limited's website at https://www.sparc.life.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SPARC:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
